Pharmaceuticals News and Research

RSS

RXi Pharmaceuticals begins Phase 1/2 clinical trial in ophthalmology

RXi Pharmaceuticals Corporation a biotechnology company focused on discovering and developing innovative therapies primarily in the areas of dermatology and ophthalmology today announced the initiation of a Phase 1/2 clinical trial in ophthalmology. The clinical study RXI-109-1501 will evaluate the safety and clinical activity of RXI-109 to prevent the progression of retinal scarring, a harmful component of numerous retinal diseases.

5 Nov 2015

American Pharmacists Association selects Elsevier as its exclusive publisher

The American Pharmacists Association has selected Elsevier, a world-leading provider of scientific, technical and medical information products and services, as its exclusive publisher, promoter and distributor of APhA publications Pharmacy Today, Journal of the American Pharmacists Association, and Journal of Pharmaceutical Sciences.

5 Nov 2015

GHIT Fund invests $10.7 million to fight malaria, TB, leishmaniasis and dengue

The Global Health Innovative Technology Fund, which in the last two years has invested US$43 million to develop innovative tools for fighting diseases worldwide, today announced it is investing $10.7 million at multiple points in the product development pipeline to seek new interventions for malaria, tuberculosis (TB), leishmaniasis and dengue.

5 Nov 2015

Men and women see lasting improvements in sex lives after bariatric surgery

Both men and women see lasting improvements in their sex lives after bariatric surgery, according to a new study, funded by the National Institutes of Health and presented here at ObesityWeek 2015, the largest international event focused on the basic science, clinical application and prevention and treatment of obesity.

5 Nov 2015

Malaria parasite hides undetected in the liver for long time before reawakening to cause disease

Eliminating malaria in the Asia-Pacific could prove more challenging than previously thought, with new research showing that most childhood malaria infections in endemic areas are the result of relapsed, not new, infections.

5 Nov 2015

Braeburn, Camurus announce FDA Fast Track designation for CAM2038 to treat opioid addiction

Braeburn Pharmaceuticals and Camurus announced today that the U.S. Food and Drug Administration granted Fast Track designation for the CAM2038 weekly and monthly buprenorphine subcutaneous injection products under development for the treatment of opioid addiction.

5 Nov 2015

Johnson & Johnson signs definitive agreement to purchase Novira Therapeutics

Johnson & Johnson today announced a definitive agreement to acquire Novira Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company developing novel therapies for curative treatment of chronic hepatitis B virus (HBV) infection.

4 Nov 2015

BD reports quarterly adjusted revenues of $3.067 billion for fourth fiscal quarter 2015

BD (Becton, Dickinson and Company), a leading global medical technology company, today reported quarterly adjusted revenues of $3.067 billion for the fourth fiscal quarter ended September 30, 2015, an increase of 39.3 percent over the prior-year period as reported, or 49.1 percent on a currency-neutral basis.

4 Nov 2015

Allergan signs licensing agreement with Mimetogen to develop, commercialize tavilermide for treatment of dry eye disease

Allergan plc, a leading global pharmaceutical company, today announced that its wholly owned subsidiary has entered into an exclusive licensing agreement with Mimetogen Pharmaceuticals, a clinical stage biotechnology company, to develop and commercialize tavilermide (MIM-D3), a topical formulation of a novel small molecule TrkA agonist for the treatment of dry eye disease.

4 Nov 2015

International research project examines effectiveness of tried and tested medicines for different diseases

The Medical University of Vienna is coordinating an international research project, which investigates the effectiveness of tried and tested medicines for the treatment of some of the heaviest burdens of our modern society including diseases such as cancer, diabetes and cardiovascular diseases. One molecule that these disorders have in common is a receptor known as the calcium-sensing receptor (CaSR), which is the molecular starting point of this project.

4 Nov 2015

New computational method helps predict adverse drug reaction better than traditional computing methods

A new integrated computational method helps predicting adverse drug reaction--which are often lethal--more reliably than with traditional computing methods. This improved ability to foresee the possible adverse effects of drugs may entail saving many lives in the future.

4 Nov 2015

Ingenza and Imperial researchers work together to improve nasogastric feeding tube placement

Ingenza has teamed up with clinical scientists at Imperial College London to trial an improved diagnostic assay for confirming nasogastric (NG) tube placement. Professor George Hanna, Director of the National Institute for Health Research Diagnostic Evidence Co-operative London at Imperial College Healthcare NHS Trust, which specialises in In Vitro Diagnostics, explained: “Correct placement of NG tubes is vital, as accidental insertion of the tube into the lung instead of the gut can have serious consequences.

3 Nov 2015

Alnylam presents positive ongoing phase 2 open-label extension data for Patisiran and Revusiran

Alnylam Pharmaceuticals, Inc. has announced new results from its ongoing Phase 2 open-label extension (OLE) studies with patisiran and revusiran, investigational RNAi therapeutics targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR amyloidosis).

3 Nov 2015

Good news for patients suffering from dry age-related macular degeneration

Scientists have good news for patients who suffer from currently untreatable dry age-related macular degeneration (dry AMD). In a new study, researchers identified a potential target for future therapies to slow the progression of the blinding condition. Published in Investigative Ophthalmology & Visual Science, the findings indicate that treatments currently used for other conditions could also work for dry AMD.

3 Nov 2015

Expert proposes new solution to current gridlock over regulation of dietary supplements

A former principal deputy commissioner of the U.S. Food and Drug Administration is proposing a solution to the current gridlock over the regulation of dietary supplements: Focus less on whether these vitamins, minerals and herbal extracts actually do what they claim and instead take important steps to improve their safety.

3 Nov 2015

$Viking begins VK5211 Phase 2 trial in patients recovering from hip fracture$

Viking begins VK5211 Phase 2 trial in patients recovering from hip fracture

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced the initiation of dosing in the company's Phase 2 clinical trial of VK5211 in patients who recently suffered a hip fracture.

3 Nov 2015

Experts call on U.S. and Mexican governments to reduce risk of Chagas disease

Chagas disease -- the third most common parasitic infection in the world -- affects approximately 7.5 million people, mostly in Latin America. To help reduce outbreaks of this disease in their countries, the United States and Mexican governments should implement a range of programs as well as fund research for the development of Chagas vaccines and treatments, according to a new policy brief by tropical-disease and science policy experts at Rice University's Baker Institute for Public Policy.

3 Nov 2015

FHI 360, Accelovance collaborate to serve international drug development research efforts

Accelovance, Inc. (Accelovance), a global contract research organization (CRO) focusing in Oncology, Vaccines, and General Medicine and FHI 360, a global nonprofit organization with CRO capabilities focusing on clinical research in developing countries, have entered into a strategic alliance to more comprehensively serve the international drug development research efforts of pharmaceutical, governmental, and nonprofit organizations.

3 Nov 2015

CureVac raises €100M to enable rapid expansion of mRNA development platform, clinical-stage pipeline

CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, today announces that it has raised about $110 million (€100 million) to enable accelerated expansion of its industry-leading messenger RNA (mRNA) development platform and clinical-stage pipeline.

3 Nov 2015

Secret tunnels used by cancer cells can be exploited to deliver drug therapies, suggests new study

A new discovery published in the Nov. 2015 issue of The FASEB Journal shows that cancer cells use previously unknown channels to communicate with one another and with adjacent non-cancerous cells.

3 Nov 2015

Pharmaceuticals News and Research

RXi Pharmaceuticals begins Phase 1/2 clinical trial in ophthalmology

American Pharmacists Association selects Elsevier as its exclusive publisher

GHIT Fund invests $10.7 million to fight malaria, TB, leishmaniasis and dengue

Men and women see lasting improvements in sex lives after bariatric surgery

Malaria parasite hides undetected in the liver for long time before reawakening to cause disease

Braeburn, Camurus announce FDA Fast Track designation for CAM2038 to treat opioid addiction

Johnson & Johnson signs definitive agreement to purchase Novira Therapeutics

BD reports quarterly adjusted revenues of $3.067 billion for fourth fiscal quarter 2015

Allergan signs licensing agreement with Mimetogen to develop, commercialize tavilermide for treatment of dry eye disease

International research project examines effectiveness of tried and tested medicines for different diseases

New computational method helps predict adverse drug reaction better than traditional computing methods

Ingenza and Imperial researchers work together to improve nasogastric feeding tube placement

Alnylam presents positive ongoing phase 2 open-label extension data for Patisiran and Revusiran

Good news for patients suffering from dry age-related macular degeneration

Expert proposes new solution to current gridlock over regulation of dietary supplements

Viking begins VK5211 Phase 2 trial in patients recovering from hip fracture

Experts call on U.S. and Mexican governments to reduce risk of Chagas disease

FHI 360, Accelovance collaborate to serve international drug development research efforts

CureVac raises €100M to enable rapid expansion of mRNA development platform, clinical-stage pipeline

Secret tunnels used by cancer cells can be exploited to deliver drug therapies, suggests new study

Free eBook - From lab to market: Accelerate your bioprocessing journey eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring